Goldman Sachs expects Nvidia ’beat and raise,’ lifts price target to $240
Cigna Corp’s stock reached a 52-week low, touching 256.66 USD, reflecting a challenging year for the company. Over the past year, the stock has experienced a decline of 17.27%, indicating significant downward pressure. According to InvestingPro data, this price represents a substantial discount to its Fair Value, suggesting the stock may be undervalued. With a P/E ratio of 16.52 and revenue growth of 20.23% over the last twelve months, Cigna’s fundamentals remain solid despite the price decline. This new low marks a notable point in the company’s recent trading history, as investors assess the broader market conditions and company-specific factors that have contributed to this performance. The decline in stock price may prompt further scrutiny from analysts and investors as they evaluate Cigna’s strategic direction and financial health moving forward. Despite market concerns, InvestingPro rates Cigna’s overall financial health as "GREAT" with a score of 3.01. Analysts maintain a bullish outlook with price targets ranging from $300 to $428, and management has been aggressively buying back shares. Cigna also offers a 2.02% dividend yield, having maintained dividend payments for 44 consecutive years.
In other recent news, The Cigna Group has introduced a new rebate-free pharmacy benefit model through its health services division, Evernorth, aimed at reducing medication costs by offering negotiated drug discounts upfront at the pharmacy counter. This initiative could potentially lower monthly costs for brand-name prescriptions by an average of 30% for consumers paying the full cost of their medications. Moody’s Ratings has affirmed The Cigna Group’s senior unsecured debt rating at Baa1 with a stable outlook, reflecting confidence in the company’s financial stability. Additionally, Cigna has announced a quarterly cash dividend of $1.51 per share, payable on December 18, 2025, to shareholders of record by December 4, 2025.
In the realm of analyst updates, Wolfe Research has lowered its price target for Cigna stock from $345 to $325 while maintaining an Outperform rating, noting the stock’s valuation at approximately nine times its revised 2026 earnings per share estimate. Meanwhile, UBS has reiterated its Buy rating on Cigna, with a maintained price target of $390, emphasizing the company’s resilience in the Managed Care sector and its strong long-term earnings growth trajectory. UBS considers Cigna as its top pick in the Healthcare Facilities & Managed Care sector, citing the company’s insulation from government business volatility and ongoing strategic initiatives. These recent developments highlight Cigna’s efforts to enhance shareholder value and maintain its competitive position in the healthcare industry.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.